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Abstract
Objective: In clinical practice there is a strong interest in non-invasive markers of nonalcoholic fatty liver disease (NAFLD). We hypothesized that the fold-change of plasma triglycerides (TG) during a 2hr oral glucose tolerance test (OGTT; 2hr TG/fasting TG, fold-changeTGOGTT), in concert with blood glucose and lipid parameters and the rs738409 C>G single nucleotide polymorphism (SNP) in PNPLA3 may improve the power of the widely used fatty liver index (FLI) to predict NAFLD. 
Design and methods: In 330 individuals at risk for type 2 diabetes, liver fat content was quantified by 1H-magnetic resonance spectroscopy. Blood glucose, insulin, liver enzymes, lipids and lipoprotein levels were measured during fasting and glucose, insulin and lipids also after a 2hr 75gr OGTT. A subgroup of 213 individuals underwent these measurements before and after 9 months of a lifestyle intervention.
Results: In all 330 subjects the fold-changeTGOGTT closely associated with liver fat content (r=0.51, p<0.0001), but predicted NAFLD less strong (ROC-AUC=0.75) than the FLI (ROC-AUC=0.79). In multivariate regression models not only the fold-changeTGOGTT, but also the 2hr blood glucose level and the rs738409 C>G SNP in PNPLA3 independently associated with liver fat content and NAFLD. A novel index (extended FLI), generated from these parameters and the parameters of the FLI, considerably increased the power of the FLI to predict NAFLD (ROC-AUC from 0.79 to 0.86). The extended FLI also increased the predictive power of the FLI to predict the change of the liver fat content after a lifestyle intervention (N=213; from std. beta 0.23 to 0.29).




Nonalcoholic fatty liver disease (NAFLD) has gained much attention in the recent years because of its high prevalence, amounting to more than 30% in the general population and to more than 70% in certain high risk groups, such as morbid obese individuals and patients with type 2 diabetes (1). NAFLD strongly associates not only with progressive hepatic, but also with metabolic diseases (2-10).
Diagnosis of NAFLD by the gold standard method, liver biopsy, is invasive and, therefore, not feasible in routine practice (11,12). Proton magnetic resonance spectroscopy (1H-MRS) is considered the most accurate non-invasive method for measuring liver fat content (13,14). However, in addition to the high costs that limit its use, the respective infrastructure and knowledge that is needed to implement this technique are only available in a limited number of institutions. Therefore, 1H-MRS is presently being applied mainly for research purposes. Routinely ultrasound is being used to diagnose NAFLD, but this technique has fair sensitivity only when liver fat content exceeds 20-30% (15). Consequently, there has been intense interest in blood markers that, alone or in combination with clinical parameters, would be able to identify patients with NAFLD. Accordingly, NAFLD or liver fat indexes were developed. However, some of them have a moderate predictive power and/or cannot be easily and widely used in the routine clinical practice, because they either involve several parameters that may not readily be measurable, or display great variability in their measurement, such as insulin, depending on the method that is being used (16-19). Furthermore, because there is a large variability in the decrease of liver fat content during a lifestyle intervention (20,21), it is important to investigate whether such indexes can predict the decrease of liver fat content during a lifestyle intervention.





Data of 330 Caucasians, 130 men and 200 women, from the southern part of Germany were analyzed. These individuals participated in the Tübingen Lifestyle Intervention Program (TULIP) (21,23). Individuals were included in the study when they fulfilled at least one of the following criteria: a family history of type 2 diabetes, a BMI > 27 kg/m2, a previous diagnosis of impaired glucose tolerance and/or of gestational diabetes. They were considered healthy according to a physical examination and routine laboratory tests. They had no history of liver disease and did not consume more than two alcoholic drinks per day. Serum aminotransferase levels were lower than 2 times the upper limit of normal. From the 330 subjects who met the aforementioned requirements, mostly due to technical reasons, a subgroup of 213 (127 women and 86 men) had a complete data set of body fat distribution and liver fat content measurements using magnetic resonance techniques both, at baseline, and at follow-up and were included in the longitudinal analyses. Informed written consent was obtained from all participants and the local medical ethics committee had approved the protocol.

Lifestyle intervention
During the intervention subjects underwent individual dietary counseling and had up to ten sessions with a dietician. The aim was to reduce body weight, intake of calories and particularly intake of calories from fat to <30% (from saturated fat to <10%) of energy consumed and to increase intake of fibers to at least 15 gr/1000 kcal. During each visit participants presented a 3-day food diary and discussed the results with the dieticians. Individuals were asked to perform at least 3 hours of moderate sports per week. Aerobic endurance exercise (e.g. walking, swimming) with an only moderate increase of the heart rate was encouraged. Participants were seen by the staff on a regular basis to ensure that these recommendations were accomplished.

Total body fat mass and body fat distribution
Body mass index was calculated as weight divided by the square of height (kg/m2). Waist circumference was measured at the midpoint between the lateral iliac crest and lowest rib. Total body- and visceral fat mass were measured by MR tomography, with an axial T1-weighed fast spin echo technique with a 1.5 T whole-body imager (Magnetom Sonata, Siemens Medical Solutions) (14,24).  

Liver fat content
Liver fat content was measured by localized 1H-MR spectroscopy (14,24). NAFLD was defined as liver fat content >5.56% (13). Liver fat content measured by this method correlates well with histomorphometric findings (25,26).

Oral glucose tolerance test
All individuals underwent a 2hr 75gr OGTT. We obtained venous plasma samples at 0, 30, 60, 90 and 120 minutes for determination of plasma glucose and insulin. Blood glucose was determined using a bedside glucose analyzer (glucose-oxidase method; YSI, Yellow Springs Instruments, Yellow Springs, CO). Plasma insulin was determined using the ADVIA Centaur XP immunoassay system (Siemens Healthcare Diagnostics, Eschborn, Germany). Insulin sensitivity from the OGTT was calculated as proposed by Matsuda and DeFronzo (27). Furthermore, the homeostasis model assessment-estimated insulin resistance (HOMA-IR) was calculated (28).

Analytical procedures
Plasma free fatty acids (FFAs), triglycerides (TGs), and total-, HDL- and low-density lipoprotein (LDL)-cholesterol were measured at 0 min, and FFA levels and TGs also at 2hr of the OGTT. Total cholesterol, HDL- and LDL-cholesterol, TGs, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase (GGT) levels were measured using the ADVIA 1800 clinical chemical analyzer (Siemens Healthcare Diagnostics, Eschborn, Germany). Plasma concentrations of total FFA were measured with an enzymatic method (WAKO Chemicals, Neuss, Germany) on the latter instrument. The SNP rs738409 C>G in PNPLA3 was genotyped as previously described (29).

Calculations of liver fat indexes
For comparison purposes, among available liver fat indices, we calculated the Fatty Liver Index (FLI) as 
[[e0.953 * loge (TG) + 0.139 * BMI +0.718 * loge (GGT) + 0.053 * (waist circumference) – 15.745] / 
[1 + e0.953 * loge (TG) + 0.139 * BMI +0.718 * loge (GGT) + 0.053 * (waist circumference) – 15.745]] * 100 (17)
and the Hepatic Steatosis Index (HSI) as 
8 * ALT/AST + BMI(+2, if type 2 diabetes; +2, if female) (19)










Demographics, anthropometrics and metabolic characteristics of the subjects
The characteristics of the 330 subjects (130 men and 200 women) who had data at baseline are shown in table 1. Subjects with NAFLD had more visceral fat mass and higher concentrations of serum liver enzymes. They also had higher glucose levels, higher 2hr FFAs, lower HDL- and higher LDL-cholesterol levels and higher fasting and 2hr TGs. Mean TG levels decreased during the OGTT, but significantly less strongly in subjects with NAFLD (table 1).

Associations of liver fat content with selected parameters
Besides the well established relationships of liver fat content with anthropometrics, glycemia and lipidemia, liver fat content was found to strongly correlate with liver enzymes, particularly GGT, fasting and 2hr TGs, 2hr glucose levels, the rs738409 C>G SNP in PNPLA3, the FLI, the HSI and with the fold-change of plasma triglycerides during the OGTT (2 hr/fasting; fold-changeTGOGTT, p<0.0001) (supplemental table 1). In univariate and multivariate relationships the FLI and the fold-changeTGOGTT emerged as the strongest determinants of liver fat content.

Determinants of NAFLD
We then explored the associations of the blood markers with NAFLD by calculating the OR of having NAFLD for 1 SD change of each of the parameters. In univariate analysis 1 SD increase (decrease for HDL-cholesterol) of all markers was significantly associated with the risk of having NAFLD (figure 1A). However, the 1 SD increase of fold-changeTGOGTT (about 15% decreases of triglycerides during the OGTT) had an almost two-fold larger effect compared to most other markers (figure 1A). In a fully adjusted model, the relationships of all markers were attenuated, with the effect of HDL-cholesterol and fasting glucose and TGs being rendered non-significant (figure 1B). Nevertheless, the effect of fold-changeTGOGTT remained greater than the effect of other markers (figure 1B). In particular, the OR for subjects having an increase of TGs during the OGTT (n=98, 29.7%) compared to those having a decrease of TGs for having NAFLD was 3.50 (95% CI, 2.12-5.78).
Next the accuracy of blood markers, the rs738409 C>G SNP in PNPLA3 and the FLI and HSI for diagnosing NAFLD was determined by calculating the areas under the ROC curves. Among the blood markers the area under the ROC curve of fold-changeTGOGTT was the largest, followed by the area under the ROC curve of GGT (table 2, univariate model). With gradual addition of gender, age, total fat mass and/or visceral fat mass in the model, the diagnostic accuracy increased; however, the area under the ROC curve of fold-changeTGOGTT remained greater than that of any other single marker (table 2, models 1-4).With regard to the liver fat indexes, FLI showed a marked higher diagnostic accuracy (area under the ROC curve 0.79) compared to HSI (area under the ROC curve 0.70).

Changes of anthropometric and metabolic characteristics during the intervention
The duration of follow-up was 8.7 ± 1.8 (mean ± SD) months. The changes of the anthropometric and metabolic parameters during the intervention are shown in the table 3. The largest change was observed for liver fat content (-30.3%), followed by visceral fat mass (-14.4%) and total fat mass (-9.1%). A resolution of NAFLD was observed in 26 from 61 (42.6%) subjects. In contrast, 9 out of 152 (5.9%) of the subjects without NAFLD at baseline developed NAFLD at follow-up. Because in the latter group body weight and fat compartments did not decrease significantly, we assume that they were not compliant with the recommendations of the study.

Predictors of the change of liver fat during the intervention
Logistic regression analysis was applied to calculate the OR for 1 standard deviation (SD) increase of the candidate blood markers at baseline for responding to the intervention with a decrease of liver fat content vs. non-responders. Again, fold-changeTGOGTT at baseline displayed the highest OR (figure 2). A decrease of 15% (1 SD) of triglycerides during the baseline OGTT was associated with a 60% larger chance of improvement of liver fat content during the intervention.
When comparing the blood markers, the rs738409 C>G SNP in PNPLA3, the FLI and the HSI, the strongest predictive effect on the change of liver fat content was seen for fold-changeTGOGTT at baseline (supplemental table 2). When adjusted for other possible confounders, HDL-cholesterol- and fasting triglyceride were not predictors of the change of liver fat content anymore. 2hr triglycerides still predicted the change of liver fat content, but the predictive effect of fold-changeTGOGTT at baseline was stronger. Among the liver fat indexes, only the FLI at baseline predicted the change of liver fat content, but weaker than the fold-changeTGOGTT (supplemental table 2).

Development of an Extended Fatty Liver Index to predict NAFLD
Based on the fact that in multivariate models the FLI, the fold-changeTGOGTT, the 2hr glucose levels during the OGTT and the rs738409 C>G SNP in PNPLA3 independently and strongly associated with liver fat content (all p<0.0001) and NAFLD [all p<0.0001, except for the rs738409 C>G SNP in PNPLA3 (p=0.002) and the 2hr glucose levels (p=0.0001)] we generated an extended FLI by using these parameters. For this we first ran a multivariate model that included the parameters of the FLI, the fold-changeTGOGTT, the 2hr glucose levels during the OGTT and the rs738409 C>G SNP in PNPLA3 (Table 4).  In analogy to the FLI we then generated a formula for the extended FLI:
Extended FLI = [[e0.4508 * loge (TG) + 0.0621 * BMI + 0.4022 * loge (GGT) + 0.0454 * (waist circumference) + 4.8874 * (fold-changeTGOGTT) + 2.4134 * loge (2hr glucose) – 1.1143 * (rs738409 C>G SNP in PNLA3) – 19.1367] / 
[1 + e0.4508 * loge (TG) + 0.0621 * BMI + 0.4022 * loge (GGT) + 0.0454 * (waist circumference) + 4.8874 * (fold-changeTGOGTT) + 2.4134 * loge (2hr glucose) – 1.1143 * (rs738409 C>G SNP in PNPLA3 ;C=1 and XG=0) – 19.1367]] * 100 




Considering the hepatic and metabolic consequences of fat accumulation in the liver (2-10), there is a strong medical need for a simple, accurate and cost-effective biomarker of liver fat content. At least four such surrogate markers have been proposed, the SteatoTest (16), the FLI (17), the NAFLD-Liver Fat Score (NAFLD-LFS) (18) and the HSI (19). Among them, the FLI was shown to predict NAFLD in several populations (2,17,30,31), but mostly with ultrasound as the reference diagnostic tool. The same holds true, albeit in only a few populations, for the HSI. Recently, studies performed a head-to-head comparison and validation of these markers against the standard methods, liver biopsy (32) and 1H-MRS (33). Both studies yielded qualitatively similar results. FLI, NAFLD-LFS and HSI displayed almost equal performance to identifying the presence of NAFLD, thus justifying their use as screening/surrogate markers. However, they did not show the same performance in quantifying liver fat content, and were not able to discriminate between mild, moderate and severe steatosis. Furthermore, it is unclear, whether these indexes are well suited for predicting the change of liver fat content in response to any pharmacological or non-pharmacological treatment of NAFLD.
In the present study we investigated whether single blood markers and the rs738409 C>G SNP in PNPLA3 can improve the power of the established liver fat indexes to predict liver fat content, the presence of NAFLD, and the decrease of liver fat content during a lifestyle intervention. For this we first focused on single markers. We further restricted the number of candidate markers to only readily measured blood parameters, the methods of measurement of which are universally established and display the highest possible repeatability and lowest possible variability within the same or between several operators and labs. 
After exploring the relationships of several routinely measured blood parameters with liver fat content, determined by the currently most accurate non-invasive method, 1H-MRS (13,14), we found that liver enzymes, particularly GGT, fasting- and 2hr glucose and TGs during an OGTT, as well as fold-changeTGOGTT, strongly associated with liver fat content. We also found that among these parameters fold-changeTGOGTT was the strongest determinant of liver fat content and the strongest predictor of NAFLD. Patients in whom TGs increased during the OGTT had a very high probability of having NAFLD, which was 3.5 times higher compared to patients in whom TGs decreased during the OGTT. Moreover, fold-changeTGOGTT at baseline was able to predict the decrease of liver fat content during a lifestyle intervention, independently of the decrease of overall and visceral adiposity. This relationship was stronger than that of any other marker. A 15% decrease of TGs during an OGTT at baseline was associated with a 60% higher chance for the intervention to be successful, i.e. to result in a reduction of liver fat content.
In the cross-sectional analyses the FLI, but not the HSI, was stronger associated with liver fat content and was able to somewhat better predict NAFLD, compared to the fold-changeTGOGTT. This was not unexpected, since fasting triglycerides are included in the formula of the FLI, and 3 additional determinants of liver fat content. Of note, when accounting for fold-changeTGOGTT, BMI and waist circumference, the prediction of NAFLD increased to 0.80 and when also gender and age were taken into consideration, the area under the ROC curve further increased to 0.83. Moreover, the fold-changeTGOGTT at baseline was a better predictor of the decrease of liver fat content during the lifestyle intervention, than the FLI at baseline. Thus, while the usefulness of the various liver fat indexes, particularly of the FLI, for diagnosing NAFLD, should not be questioned, fold-changeTGOGTT could also be used as a screening parameter for identifying patients potentially having NAFLD, and may additionally represent a useful predictor of the change of liver fat content over time.
The precise mechanisms linking liver fat content with the change of triglycerides during the OGTT are unknown. In most cases, triglyceride levels decrease during an OGTT. This is thought to be a result of the increase of insulin levels in response to the glucose load. High insulin levels suppress adipocyte lipolysis and FFA supply to the liver, ultimately leading to a decrease of VLDL production and triglyceride levels (34). Furthermore, insulin may suppress VLDL secretion independently of FFA influx through direct action on the liver. In addition, insulin directly enhances intravascular triglyceride hydrolysis by increasing the activity of lipoprotein lipase (LPL) and it stimulates hepatic low density lipoprotein-related protein-1 (LRP1), thereby increasing catabolism of triglyceride-rich VLDL and chylomicron particles (35,36). On the other hand, elevated glucose during the OGTT may counteract the effects of insulin by substrate competition with fatty acids, suppressing hepatic fatty acid oxidation and stimulating lipogenesis as well as VLDL production in the liver (37). It is plausible that the aforementioned effects of insulin would weaken with increasing insulin resistance, and eventually, the effects of hyperglycemia would prevail. This would lead to an increase of triglycerides levels, during the OGTT, preferentially in insulin resistant subjects with abdominal obesity, as observed in the present, and in other studies (22). 
After having established that parameters of the FLI, as well as the fold-changeTGOGTT, the 2hr glucose levels and the rs738409 C>G SNP in PNPLA3 are strongly associated with NAFLD, we used these parameters to develop an extended FLI. This novel index was found to have a higher ROC-AUC for predicting NAFLD than the FLI. At the cut-off values 30 (lower values are thought to exclude NAFLD) and 60 (higher values are thought to prove NAFLD) the extended FLI was found to have lower sensitivity, however, higher specificity to predict NAFLD. Furthermore, while at these cut-off values the negative predictive values were smaller for the extended FLI compared to the FLI, the respective positive predictive values were larger. Thus, these data indicate that for a value ≥60 the extended FLI is better suited than the FLI to diagnose NAFLD, whereas, for a value <30 the FLI appears to be somewhat better suited to exclude NAFLD.
Our study has some limitations. We only studied Caucasians at risk for type 2 diabetes. Thus, there is an obvious need for validation of our findings in other ethnic groups and in patients with type 2 diabetes. Particularly in the latter group, other biomarkers, including FLI and HSI, showed a relatively low ability for predicting NAFLD (38). Furthermore, although there was great variability and range in nearly all anthropometric and metabolic parameters across the participants of the present study, our population included no subjects with extremely high liver fat content. Since the accuracy of other biomarkers for diagnosing such high levels of liver fat content is low (32), the findings of the present study may not fully apply to subjects with this phenotype. Nevertheless, the fact that in an Italian population with biopsy-proven NAFLD (personal communication with A. Gastaldelli and E. Bugianesi; N=23, mean age=42 years) the fold-changeTGOGTT measured during a 2hr 75g OGTT was found to be 1.01, which is very similar to the ratio in the German population with NAFLD, supports that the fold-changeTGOGTT could be used to estimate the risk of NAFLD. Finally, the calculation of our proposed extended FLI requires the performance of a 2hr OGTT and the determination of the rs738409 C>G SNP in PNPLA3. However, as diagnosis of prediabetes and diabetes becomes more important today, particularly in subjects with suspected NAFLD, OGTTs will be more often incorporated in the clinical setting. Furthermore, genotyping of the most important genetic determinant of NAFLD, NASH and possibly fibrosis, may also become a routine diagnostic approach in clinical practice. 
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Table 1 Subjects’ demographic and metabolic characteristics.

	All	Subjects without NAFLD	Subjects with NAFLD	p
Demographics				
Gender (females / males)	200 / 130	150 / 75	50 / 55	0.001*
Age (years)	45.5 ± 0.7	44.2 ± 0.8	48.2 ± 1.1	0.002
				
Body composition				
Body weight (kg)	86.39 ± 0.93	82.92 ± 1.06	93.82 ± 1.63	<0.0001
Body mass index (kg·m-2)	29.50 ± 0.27	28.34 ± 0.31	31.99 ± 0.45	<0.0001
Waist circumference (cm)	96.5 ± 0.7	92.7 ± 0.8	104.6 ± 1.1	<0.0001
Total body fat (kg)	26.16 ± 0.58	24.57 ± 0.69	29.59 ± 1.01	<0.0001
Subcutaneous abdominal fat (kg)	11.35 ± 0.27	10.57 ± 0.32	13.04 ± 0.49	<0.0001
Visceral fat (kg)	2.95 ± 0.10	2.37 ± 0.10	4.20 ± 0.18	<0.0001
Liver fat (%)	5.80 ± 0.35	2.38 ± 0.11	13.14 ± 0.64	<0.0001
Fatty liver (n)	105 (31.82%)		-----	-----
				
Metabolic characteristics				
ALT (U/L)	28.77 ± 1.07	25.95 ± 0.99	34.93 ± 2.51	<0.0001
AST (U/L)	24.86 ± 0.61	23.00 ± 0.50	28.75 ± 1.49	<0.0001
GGT (U/L)	27.34 ± 1.53	23.43 ± 1.65	35.79 ± 3.14	<0.0001
Fasting glucose (mM)	5.26 ± 0.03	5.18 ± 0.03	5.44 ± 0.06	<0.0001
2 h glucose (mM)	7.07 ± 0.10	6.75 ± 0.11	7.75 ± 0.21	<0.0001
Fasting insulin (pM)	62.1 ± 2.3	52.5 ± 2.1	82.4 ± 4.9	<0.0001
2 h insulin (pM)	498.8 ± 21.3	395.9 ± 20.4	717.3 ± 43.3	<0.0001
Fasting free fatty acids (μM)	660 ± 15	658 ± 18	665 ± 24	0.66
2 h free fatty acids (μM)	77 ± 4	66 ± 4	95 ± 6	<0.0001
Fasting TG (mg/dl)	112.71 ± 4.45	101.81 ± 4.66	135.56 ± 9.36	<0.0001
2hr TG (mg/dl)	104.89 ± 4.26	90.75 ± 4.33	134.67 ± 8.96	<0.0001
Fold-changeTGOGTT (2hr TG/fasting TG)	0.912 ± 0.008	0.872 ± 0.010	0.997 ± 0.011	<0.0001
AUC0-2hr TG (mg/dl)	220.25 ± 8.72	196.26 ± 9.20	270.32 ± 17.95	<0.0001
Total cholesterol (mg/dl)	194.7 ± 2.0	193.3 ± 2.5	197.8 ± 3.1	0.15
HDL-cholesterol (mg/dl)	52.3 ± 0.7	54.2 ± 0.9	48.2 ± 1.1	<0.0001
LDL-cholesterol (mg/dl)	123.2 ± 1.7	120.3 ± 2.0	129.3 ± 2.9	0.008
HOMA-IR index 	1.99 ± 0.08	1.65 ± 0.07	2.72 ± 0.17	<0.0001
Insulin sensitivityOGTT (arb. units)	12.73 ± 0.40	14.62 ± 0.46	8.72 ± 0.46	<0.0001
rs738409 C>G SNP in PNPLA3				
CC 	188	137	51	
XG	142	88	54	0.03*
Fatty Liver Index	50.68 ± 1.60	41.40 ± 1.82	70.75 ± 2.12	<0.0001
Hepatic Steatosis Index	39.91 ± 0.36	38.55 ± 0.42	42.76 ± 0.58	<0.0001

p for the difference between NAFLD and non-NAFLD patients (unadjusted, t-test) * chi-square
Values represent unadjusted means ± SE (standard error). For statistical analyses, non-normally distributed parameters were log transformed. § available in 222 subjects (68 with and 154 without NAFLD) ISI, insulin sensitivity index; AUC: area under the curve


Table 2 Accuracy of selected blood markers for diagnosing nonalcoholic fatty liver disease (area under the Receiver Operating Characteristic curve)













1Model 1: Adjusted for gender and age
2Model 2: Adjusted for gender, age and total fat mass
3Model 3: Adjusted for gender, age and visceral fat mass
4Model 4: Adjusted for gender, age, total adipose fat mass and visceral fat mass
#dominant model (CC vs XG)


Table 3 Demographic and metabolic characteristics of subjects who participated in the lifestyle intervention.
Parameter	All subjects	Subjects without NAFLDat baseline	Subjects with NAFLDat baseline
	Baseline	Follow-up		Baseline	Follow-up	p	Baseline	Follow-up	p
Gender (females / males)	127 / 86		103 / 49		24 / 37	
Age (years)	45.7 ± 0.8	46.4 ± 0.8	<0.0001	45.1 ± 0.9	45.8 ± 0.9	<0.0001	47.3 ± 1.4	48.1 ± 1.4	0.0015
Body weight (kg)	85.6 ± 1.1	83.1 ± 1.1	<0.0001	82.2 ± 1.2	80.1 ± 1.2	0.032	94.1 ± 2.0	90.7 ± 2.1	0.024
Body mass index (kg∙m-2)	29.04 ± 0.32	28.19 ± 0.31	<0.0001	27.99 ± 0.36	27.27 ± 0.35	0.031	31.64 ± 0.54	30.47 ± 0.54	0.024
Waist circumference (cm)	95.9 ± 0.9	92.6 ± 0.8	<0.0001	92.2 ± 1.0	89.2 ± 0.9	0.008	105.2 ± 1.5	100.9 ± 1.5	0.076
Total body fat (kg)	25.40 ± 0.68	23.08 ± 0.67	0.013	24.18 ± 0.80	22.13 ± 0.78	0.10	28.43 ± 1.21	25.45 ± 1.27	0.024
Subcutaneous abdominal fat (kg)	10.86 ± 0.31	10.16 ± 0.31	0.0015	10.24 ± 0.36	9.71 ± 0.35	0.036	12.40 ± 0.60	11.27 ± 0.60	0.008
Visceral fat (kg)	2.92 ± 0.13	2.52 ± 0.12	<0.0001	2.36 ± 0.12	2.00 ± 0.11	<0.0001	4.33 ± 0.24	3.82 ± 0.27	0.0002
Liver fat MRS (%)	5.34 ± 0.42	3.72 ± 0.28	0.0005	2.20 ± 0.11	1.98 ± 0.14	0.012	13.18 ± 0.83	8.05 ± 0.64	0.033
NAFLD	61 (28.6%)	44 (20.7%)	<0.0001	0 (0%)	9 (5.9%)		61 (100%)	35 (57.4%)	
ALT (U/L)	27.65 ± 1.06	24.08 ± 1.03	<0.0001	25.76 ± 1.25	21.80 ± 1.13	<0.0001	32.33 ± 1.86	29.85 ± 2.07	0.024
AST (U/L)	25.14 ± 0.80	23.27 ± 0.53	0.047	23.09 ± 0.61	22.42 ± 0.51	0.32	30.11 ± 2.20	25.70 ± 1.37	0.12
GGT (U/L)	26.45 ± 1.91	25.47 ± 2.05	0.11	21.59 ± 1.79	22.32 ± 2.39	0.54	38.56 ± 4.64	33.40 ± 3.83	0.16
Fasting glucose (mM)	5.26 ± 0.04	5.18 ± 0.04	0.022	5.18 ± 0.04	5.14 ± 0.04	0.48	5.45 ± 0.08	5.29 ± 0.08	0.16
2hr glucose (mM)	6.93 ± 0.11	6.71 ± 0.11	0.013	6.64 ± 0.11	6.59 ± 0.13	0.041	7.67 ± 0.22	7.02 ± 0.23	0.56
Fasting insulin (pM)	59.1 ± 2.4	52.3 ± 2.2	0.0002	51.0 ± 2.2	45.6 ± 2.0	0.11	79.1 ± 5.2	69.0 ± 5.2	0.23
2hr insulin (pM)	491.1 ± 26.2	429.2 ± 27.4	0.001	399.5 ± 25.0	372.7 ± 24.9	0.08	717.9 ± 57.5	570.1 ± 70.3	0.0496
Fasting free fatty acids (μM)	667 ± 18	600 ± 14	0.003	674 ± 23	612 ± 16	0.99	648 ± 25	570 ± 30	0.07
2hr free fatty acids (μM)	78 ± 5	77 ± 12	0.0004	68 ± 6	80 ± 17	0.23	130 ± 9	70 ± 6	0.64
Fasting TG (mg/dl)	112.8 ± 5.9	107.0 ± 5.9	0.006	104.8 ± 6.3	96.3 ± 6.0	0.018	132.9 ± 13.3	134.2 ± 13.7	0.029
2rh TG (mg/dl)	103.7 ± 5.6	94.5 ± 5.4	<0.0001	92.1 ± 5.9	81.6 ± 5.6	0.004	132.4 ± 12.5	127.1 ± 11.9	0.014
Fold-changeTGOGTT (2hr/fasting)	0.90 ± 0.01	0.87 ± 0.01	0.0007	0.86 ± 0.01	0.83 ± 0.01	0.25	1.00 ± 0.02	0.95 ± 0.02	0.17
AUC0-120 TG (mg/dl)	219.0 ± 11.6	202.2 ± 11.1	0.001	200.3 ± 12.5	179.2 ± 11.5	0.008	265.4 ± 25.2	260.4 ± 24.8	0.023
Total cholesterol (mg/dl)	193.5 ± 2.6	191.0 ± 2.7	0.16	193.1 ± 3.2	189.3 ± 3.1	0.07	194.4 ± 4.0	195.5 ± 5.1	0.09
HDL-cholesterol (mg/dl)	52.7 ± 0.9	52.7 ± 0.9	0.38	54.6 ± 1.1	54.5 ± 1.2	0.45	48.07 ± 1.5	48.07 ± 1.4	0.73
LDL-cholesterol (mg/dl)	121.5 ± 2.1	117.6 ± 2.3	0.013	119.2 ± 2.5	115.1 ± 2.7	0.16	127.2 ± 3.7	123.8 ± 4.4	0.57
HOMA-IR index	1.89 ± 0.08	1.64 ± 0.07	<0.0001	1.61 ± 0.08	1.43 ± 0.07	0.11	2.60 ± 0.18	2.19 ± 0.17	0.18
Insulin sensitivityOGTT (AU)	12.96 ± 0.47	14.80 ± 0.54	<0.0001	14.51 ± 0.54	16.25 ± 0.64	0.19	9.11 ± 0.69	11.18 ± 0.83	0.013
ISIclamp(μmol•kg-1•min-1•pM-1)§	0.067 ± 0.003	0.078 ± 0.008	0.22	0.076 ± 0.004	0.086 ± 0.009	0.58	0.044 ± 0.003	0.053 ± 0.009	0.56
Fatty Liver Index	48.18 ± 2.05	41.98 ± 2.04	<0.0001	39.26 ± 2.23	33.49 ± 2.15	<0.0001	70.39 ± 3.01	63.35 ± 3.44	0.002
Hepatic Steatosis Index	39.10 ± 0.40	38.31 ± 0.56	0.001	38.05 ± 0.47	37.21 ± 0.68	0.004	41.62 ± 0.65	41.45 ± 0.83	0.059
§ n= 162 at baseline (45 with and 117 without NAFLD) and 44 at follow-up (11 with and 33 without NAFLD) .














rs738409 C>G SNP in PNPLA3#	-1.1143	0.3104	12.8876	0.0003


































Odds ratios (OR) for 1 standard deviation (SD) higher baseline alanine transferase (ALT). aspartate transferase (AST). gamma-glutamyltranspeptidase (GGT). HDL-cholesterol. fasting- and 2hr glucose triglycerides (TG) during a 2hr 75g oral glucose tolerance test (OGTT). and fold-change of TGs during the OGTT (2hr/fasting; fold-changeTGOGTT) for having non-alcoholic fatty liver disease (NAFLD) in univariate analyses (panel A) and in multivariate analyses with additional adjustment for gender. age. total adipose tissue and visceral adipose tissue mass (panel B).

Figure 2
Odds ratios (OR) for 1 standard deviation (SD) higher baseline alanine aminotransferase (ALT). aspartate aminotransferase (AST). gamma-glutamyl transpeptidase (GGT). HDL-cholesterol. fasting- and 2hr glucose and triglycerides (TG) during a 2hr 75g oral glucose tolerance test (OGTT). and fold-change of TGs during the OGTT (2hr/fasting; fold-changeTGOGTT) for responding to the intervention in terms of liver fat content. i.e. for reducing vs. increasing or maintain the same liver fat content. Models were adjusted for liver fat content at baseline (panel A) or. additionally. for gender. age. total adipose tissue and visceral adipose tissue mass at baseline (panel B).

Figure 3
Prediction of NAFLD by calculating the fatty liver index (FLI) and the newly developed extended FLI in cross-sectional data.
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